ESC 365 - Doctor Stephen Greene

Speaker illustration

Doctor Stephen Greene

Duke Clinical Research Institute, Durham (United States of America)

Member of:

Heart Failure Association

Dr. Greene is a heart failure cardiologist in the Division of Cardiology and Duke Clinical Research Institute, at the Duke University School of Medicine. Dr. Greene’s research focuses on improving quality of care and outcomes for patients with heart failure. He has been a co-investigator and co-author of multiple national and international heart failure trials studying medical therapies for heart failure, including the ASTRONAUT, SOCRATES-Reduced, COMPOSE, and TRANSFORM-HF trials. He has also led multiple analyses from national registries characterizing the quality of heart failure care in U.S. clinical practice, including studies leveraging the CHAMP-HF registry, American Heart Association’s Get With The Guidelines Heart Failure registry, and the VICTORIA registry. Dr. Greene’s collaborative work has led to more than 300 publications in peer-reviewed journals.

Presentations Articles

The risks of omission in heart failure management

Event: ESC Congress 2024

Topic: Chronic Heart Failure

Session: The risk of omission: speeding up the implementation of guideline-directed heart failure therapy

Expert panel discussion and Q&A

Event: ESC Congress 2024

Topic: Pathophysiology and Mechanisms

Session: A three-step approach for the treatment of patients with worsening heart failure

Step 3 - time is prognosis: rapid treatment optimisation

Event: ESC Congress 2024

Topic: Pathophysiology and Mechanisms

Session: A three-step approach for the treatment of patients with worsening heart failure

Panel discussion & audience Q&A - accelerating the adoption of GDMT

Event: Heart Failure 2024

Topic: Chronic Heart Failure

Session: A race against time: accelerating the adoption of GDMT in heart failure

The implication of delayed diagnosis and sub-optimal GDMT

Event: Heart Failure 2024

Topic: Chronic Heart Failure

Session: A race against time: accelerating the adoption of GDMT in heart failure

Sacubitril/valsartan and cardiovascular biomarkers among patients with recent COVID-19 infection: the PARACOR-19 randomized clinical trial

Event: Heart Failure 2024

Topic: Biomarkers

Session: ePosters in chronic heart failure - biomarkers 1

Clinician perceptions and reasons for non-use of guideline-directed medical therapy for heart failure with reduced ejection fraction in the United States

Event: ESC Congress 2023

Topic: Pharmacotherapy

Session: Pharmacotherapy in heart failure

Audience Q&A

Event: ESC Congress 2023

Topic: Chronic Heart Failure

Session: Implementing heart failure guidelines with collaborative care

Early/rapid initiation of GDMT- case vignette and discussion

Event: ESC Congress 2023

Topic: Chronic Heart Failure

Session: Implementing heart failure guidelines with collaborative care

Addressing new guidelines - discussion

Event: ESC Congress 2023

Topic: Chronic Heart Failure

Session: Implementing heart failure guidelines with collaborative care

ESC 365 is supported by

Explore sponsored resources